Here we take a close look at two upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. Xtandi could very well be a game-changer for Medivation. Vivus posted extremely postive results off late but there are reasons to worry if you are an investor of Vivus. Let’s take a closer look at the three stocks. Medivation gained 8.5% even though … Continue reading Active Biotech Stocks: Medivation & Vivus

Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. All three stocks: Clovis, Biogen & Halozyme have shown some promise in the past and would hope to continue their run of form in the coming months. Let’s take a closer look at the three stocks. Clovis’ shares slumped 19.9% on safety concerns … Continue reading Biotech Stocks Roundup: Clovis, Biogen & Halozyme

Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. While Sarepta has shown mediocre results in the past few weeks, the stock may be looking for a comeback in the coming times. On the other hand, both Regeneron and Ariad are looking strong as we head into August. Let’s take a closer … Continue reading Biotech Stocks to Target: Sarepta Therapeutics, Regeneron Pharma. & Ariad

AbbVie’s (ABBV) efforts to acquire Ireland-based Shire (SHPG) remains the top news in the biotech market segment. Meanwhile, Gilead Sciences Inc’s (GILD) hepatitis C drug made it to the news yet again thanks to its price tag. Also making it to the news is Clegene Corp. Let’s take a closer look at the three stocks. AbbVie, which has been looking to acquire Shire for a … Continue reading Bullish Biotech Stocks in News: AbbVie, Gilead Sciences Inc & Celgene Corp